The thrombin receptor PAR-1 is activated by cl-thrombin to stimulate cells,
including platelets, through the tethered-ligand sequence SFLLRN. We have
discovered a novel series of heterocycle-peptide hybrids comprised of a tri
peptide segment, such as Cha-Arg-Phe, and an N-terminal heterocyclic group,
many of which behave as full PAR-1 agonists. Certain compounds with an ami
notriazole group, such as 4 and 16, are nearly as potent as SFLLRN-NH2, in
inducing platelet aggregation. Also, some arylethenoyl "N-capped" compounds
, such as 52 and 57, exhibit mixed PAR-1 agonist-antagonist activity. (C) 1
999 Elsevier Science Ltd. All rights reserved.